232 related articles for article (PubMed ID: 35069416)
21. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
[TBL] [Abstract][Full Text] [Related]
22. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
[TBL] [Abstract][Full Text] [Related]
23. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.
Scheffler A; Basten J; Menzel L; Binz D; Becker WA; Breunung V; Schenk H; Kleinschnitz C; Nsaka M; Lindner D; Holle D
J Headache Pain; 2024 Jul; 25(1):109. PubMed ID: 38965463
[TBL] [Abstract][Full Text] [Related]
24. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
Driessen MT; Cohen JM; Thompson SF; Patterson-Lomba O; Seminerio MJ; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 May; 23(1):56. PubMed ID: 35578182
[TBL] [Abstract][Full Text] [Related]
25. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.
Toni T; Tamanaha R; Newman B; Liang Y; Lee J; Carrazana E; Vajjala V; Viereck J; Liow KK
Neurol Sci; 2021 Dec; 42(12):5373-5376. PubMed ID: 34409517
[TBL] [Abstract][Full Text] [Related]
27. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.
Argyriou AA; Dermitzakis EV; Xiromerisiou G; Vikelis M
Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548744
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
[TBL] [Abstract][Full Text] [Related]
29. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ
Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838
[TBL] [Abstract][Full Text] [Related]
31. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
[TBL] [Abstract][Full Text] [Related]
32. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
Chase BA; Semenov I; Rubin S; Meyers S; Mark A; Makhlouf T; Chirayil TT; Maraganore D; Wei J; Zheng SL; Xu J; Epshteyn A; Pham A; Frigerio R; Markopoulou K
Headache; 2024 Jan; 64(1):68-92. PubMed ID: 38071464
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study.
Driessen MT; Cohen JM; Patterson-Lomba O; Thompson SF; Seminerio M; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 Apr; 23(1):47. PubMed ID: 35410121
[TBL] [Abstract][Full Text] [Related]
34. Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
Silberstein SD; Reshef S; Cohen JM; Gandhi S; Seminerio M; Ramirez Campos V; Kessler Y; Thompson SF; Blumenfeld A
Adv Ther; 2023 Feb; 40(2):445-459. PubMed ID: 36350532
[TBL] [Abstract][Full Text] [Related]
35. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
Salim A; Hennessy E; Sonneborn C; Hogue O; Biswas S; Mays M; Suneja A; Ahmed Z; Mata IF
CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127
[TBL] [Abstract][Full Text] [Related]
36. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
Varnado OJ; Vu M; Buysman EK; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
Curr Med Res Opin; 2024 Apr; 40(4):635-646. PubMed ID: 38334320
[TBL] [Abstract][Full Text] [Related]
37. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
Muñoz-Vendrell A; Campoy S; Caronna E; Alpuente A; Torres-Ferrus M; Nieves Castellanos C; Olivier M; Campdelacreu J; Prat J; Camiña Muñiz J; Molina Martínez FJ; Mínguez-Olaondo A; Ruibal Salgado M; Santos Lasaosa S; Navarro Pérez MP; Morollón N; López Bravo A; Cano Sánchez LM; García-Sánchez SM; García-Ull J; Rubio-Flores L; Gonzalez-Martinez A; Quintas S; Echavarría Íñiguez A; Gil Luque S; Castro-Sánchez MV; Adell Ortega V; García Alhama J; Berrocal-Izquierdo N; Belvís R; Díaz-Insa S; Pozo-Rosich P; Huerta-Villanueva M
J Headache Pain; 2023 Jun; 24(1):63. PubMed ID: 37268904
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
40. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H; Holle D; Nsaka M; Kleinschnitz C; Glas M; Scheffler A
J Headache Pain; 2022 May; 23(1):55. PubMed ID: 35538414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
